Investigational drug · Phase 2
SCG142
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 17, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SCG142"
First trial start
2024
Oct 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCG142", any sponsor or status.
Conditions studied
As listed on its trial records.
- HPV-Related Squamous Cell Carcinoma
- HPV-Related Cervical Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vaginal Squamous Cell Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Head and Neck Cancer
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SCG142" as an intervention, largest first.
- Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive CarcinomaNot yet recruiting
SCG Cell Therapy Pte. Ltd.Industry
NCT06505551 · 66 participants (planned) · Start Oct 2024 · Primary completion Dec 2026
Drug: SCG142; Cyclophosphamide and 1 more · For: HPV-Related Squamous Cell Carcinoma; HPV-Related Cervical Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma and 4 more
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
NCT06544720 · 18 participants (planned) · Start Aug 2, 2023 · Primary completion Dec 31, 2025
Drug: SCG142 TCR-T cells · For: Human Papillomavirus Associated Carcinomas; Cervical Cancer; Head and Neck Cancers and 5 more
Sites: Qingdao, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HPV-Related Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.